Previous Close | 486.40 |
Open | 485.30 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 483.20 - 496.60 |
52 Week Range | 308.40 - 600.90 |
Volume | |
Avg. Volume | 103,234 |
Market Cap | 35.8B |
Beta (5Y Monthly) | 0.64 |
PE Ratio (TTM) | 0.12 |
EPS (TTM) | 39.52 |
Earnings Date | Jul 25, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Explore key insights from Acumen Pharmaceuticals' Q1 2024 earnings, focusing on their innovative Alzheimer's treatments and financial outlook.
Despite a net loss, MRVI showcases strategic expansions and robust partnerships, setting the stage for future growth.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.